Germany has emerged as a premier global hub for Antibody-Drug Conjugate (ADC) innovation, driven by a unique synergy between world-class academic research and a robust biopharmaceutical ecosystem. From the invention of high-stability conjugation chemistries at institutes like the Leibniz-FMP to the multi-billion-dollar clinical pipelines of BioNTech and Merck KGaA, the country leads in developing "next-generation" targeted therapies.

This landscape is characterised by a mix of pioneering biotechs (e.g., Tubulis, Heidelberg Pharma) that focus on novel payloads like Amanitin and ultra-stable linkers, and major pharmaceutical players aggressively expanding their oncology portfolios through strategic acquisitions and licensing. The following table provides a comprehensive overview of the home-grown and international companies and research institutes shaping the future of ADC development in Germany.